<DOC>
	<DOCNO>NCT02257489</DOCNO>
	<brief_summary>This study evaluate safety tolerability single multiple dos ACE-083 local injection select skeletal muscle healthy subject . The study also determine amount ACE-083 reach systemic circulation follow local administration . Additionally , study ass whether local administration skeletal muscle result increase size and/or strength inject muscle .</brief_summary>
	<brief_title>Phase 1 Study ACE-083 Healthy Subjects</brief_title>
	<detailed_description>ACE-083 molecule show increase skeletal muscle mass animal , therefore , potential utility certain disease affect skeletal muscle . This initial study healthy human subject help determine property ACE-083 ( safety , tolerability , drug absorption biologic activity ) , follow local administration skeletal muscle , advance clinical trial patient . The study consist 7 plan group 8 9 subject . Subjects cohort randomize receive either ACE-083 placebo . ACE-083 ( placebo ) administer locally right quadriceps ( thigh ) muscle right tibialis anterior ( low leg ) muscle . Subjects receive total either one dose ( Day 1 ) two dos ( Day 1 Day 22 ) . Each dose administer could include 4 injection study drug pre-defined location muscle . A Safety Review Team ( SRT ) review blind , preliminary data treatment group make recommendation regard escalation next treatment group . Subjects assess safety throughout treatment follow-up period . Follow-up visit occur 12 week follow last dose study drug .</detailed_description>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<criteria>Postmenopausal woman , define follicle stimulate hormone ( FSH ) level &gt; 40 IU/L either 12 month spontaneous amenorrhea least 6 month postsurgical bilateral oophorectomy and/or hysterectomy BMI 18.532 kg/m2 Clinical laboratory value meet follow criterion prior dose Study Day 1 : ( ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2 x upper limit normal ( ULN ) , ( ii ) Calculated creatinine clearance ≥ 60 mL/min , ( iii ) Platelet count ≥ 100 x109/L Able adhere study visit schedule , understand comply protocol requirement Understand sign write informed consent History hepatitis B ( HBsAg HB core Ab ) , human immunodeficiency virus ( HIV ) antibody active hepatitis C Positive drug alcohol screen test screen Day 1 History drug alcohol abuse ( define Investigator ) require treatment drug alcohol use within 2 year Day 1 Donation loss ≥ 500 mL whole blood within 2 month prior Day 1 History opportunistic infection ( e.g. , invasive candidiasis pneumocystis pneumonia ) within 6 month prior screen ; serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , septicemia ) within 3 month prior screen History severe allergic anaphylactic reaction hypersensitivity recombinant proteins History active malignancy , exception fully excise treat basal cell carcinoma , cervical carcinoma insitu , ≤ 2 squamous cell carcinoma skin History clinically significant ( determined Investigator ) cardiac , endocrine , hematologic , hepatic , immune , metabolic , urologic , pulmonary , neurologic , neuromuscular , dermatologic , psychiatric , renal , and/or disease Treatment systemic glucocorticoid therapy , statin medication , insulin , oral hormone replacement therapy therapy ( include investigational ) know intended effect muscle within 3 month prior Day 1 Treatment antiplatelet , anticoagulant , therapy ( include investigational ) know intended effect bleed risk within 1 week prior Day 1 Treatment another investigational drug , approve therapy investigational use within 4 week prior Day 1 , halflife previous product know , within 5 time halflife prior Day 1 , whichever longer Treatment within 3 month prior Day 1 potent cytochrome P450 ( CYP ) 3A4/5 inhibitor ( e.g. , verapamil , ketoconazole , micronazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , delavirdine ) CYP3A4/5 inducer ( carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John 's wort ) Subject unwilling unable maintain physical activity baseline level duration study Subject condition would prevent MRI scan ( e.g. , pacemaker , knee/hip replacement , metallic implant , extreme claustrophobia ) Subject unsuitable enrollment opinion Investigator Sponsor unspecified reason</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>